Close Menu

vaccines

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

Million a Day

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

Dip Possible

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.

Moderna says it would be able to quickly update its SARS-CoV-2 vaccine to address new genetic variants if needed, MIT's Technology Review reports.

According to CNN, Brazil has announced that a SARS-CoV-2 vaccine developed by China's Sinovac has a lower effectiveness rate than initially thought.

Still Seems to Work

The Associated Press reports a preliminary study suggests the Pfizer-BioNTech vaccine is effective against the new SARS-CoV-2 variant.

South African researchers are investigating whether COVID-19 vaccines are effective against a SARS-CoV-2 strain recently identified there, the Associated Press reports.

Second Vaccine for EU

The Wall Street Journal reports the European Medicines Agency has approved Moderna's SARS-CoV-2 vaccine.

China has approved a SARS-CoV-2 vaccine developed by the state-owned Sinopharm, according to NPR.

Pages

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.